Immunomedics to Report Second Quarter 2019 Results and Host Conference Call and Webcast on August 7, 2019
August 01, 2019 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Participate in Upcoming Healthcare Conferences
May 29, 2019 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., May 29, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Reports First Quarter 2019 Results and Provides Corporate Update
May 09, 2019 07:00 ET
|
Immunomedics
Agreement with Janssen Established to Co-Promote Balversa Sacituzumab Govitecan Licensed to Everest Medicines for Greater China and Certain Asian Countries Resubmission of Biologics License...
Immunomedics To Participate In Upcoming Healthcare Conferences
May 07, 2019 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Report First Quarter 2019 Results and Host Conference Call and Webcast on May 9, 2019
May 02, 2019 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan
April 29, 2019 07:40 ET
|
Immunomedics
The Largest Single-Asset License Agreement for Greater China To Date Provides Everest Medicines the Right to Develop and Commercialize Sacituzumab Govitecan for All Cancer Indications in Greater...
Immunomedics Announces Departure of Chief Medical Officer
April 29, 2019 07:35 ET
|
Immunomedics
MORRIS PLAINS, N.J., April 29, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Promotion Agreement With Janssen for Erdafitinib in the U.S.
April 08, 2019 09:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Appoints Barbara G. Duncan to Board of Directors
March 07, 2019 16:01 ET
|
Immunomedics
MORRIS PLAINS, N.J., March 07, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Participate in Cowen and Company 39th Annual Health Care Conference
March 04, 2019 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., March 04, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...